Kitov Announces Retirement of Founder and Executive Chairman Dr. Paul Waymack
02 mai 2019 16h45 HE
|
Kitov Pharma Ltd.
Dr. Waymack Will Continue to Serve as Kitov's Medical and Regulatory Advisor TEL AVIV, Israel, May 02, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (the “Company” or “Kitov”) (NASDAQ/TASE:...
Kitov Announces Key Milestone in FameWave Acquisition
12 avr. 2019 08h28 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, April 12, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative pharmaceutical company developing first-in-class combination oncology therapies, today...
Kitov to Acquire Clinical Stage Candidate CM-24 Creating a Transformational Immuno-Oncology Company
14 mars 2019 09h09 HE
|
Kitov Pharma Ltd.
- Transaction adds immune oncology candidate to Kitov’s pipeline which includes promising NT-219 cancer drug resistance prevention therapeutic candidate - Kitov to receive $3.5M investment from...
Kitov Pharma Reports Year End 2018 Financial Results and Provides Business Update
07 févr. 2019 08h06 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today reported its unaudited financial results for the year ended December...
Kitov Closes $6 Million Registered Direct Offering
18 janv. 2019 16h30 HE
|
Kitov Pharma Ltd.
TEL-AVIV, Israel, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today announced the closing of its previously announced registered...
Kitov Announces Pricing of $6 Million Registered Direct Offering
16 janv. 2019 13h35 HE
|
Kitov Pharma Ltd.
TEL-AVIV, Israel , Jan. 16, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced that it has entered into definitive agreements...
New Data on Kitov’s NT219 Demonstrates its Unique Mechanism of Action and Anti-Cancer Effect
15 janv. 2019 08h41 HE
|
Kitov Pharma Ltd.
NT219 is a first-in-class drug candidate with high affinity and selectivity to its target proteinsData show that even a short exposure of cancerous cells to NT219 was sufficient to trigger...
Kitov Signs Marketing and Distribution Agreement for its Lead Product Consensi™ in the U.S. with Coeptis Pharmaceuticals
03 janv. 2019 07h19 HE
|
Kitov Pharma Ltd.
- Kitov to receive $3.5M milestone payments and 40% - 60% of net profit on sales of Consensi ™- Coeptis to cover all CMC, sales, and marketing expenses TEL AVIV, Israel, Jan. 03, 2019 (GLOBE...
Kitov Appoints Gil Efron as Deputy Chief Executive Officer and Chief Financial Officer
11 oct. 2018 08h26 HE
|
Kitov Pharma Ltd.
Simcha Rock to Retire as CFO and Remain on Kitov’s Board of Directors TEL AVIV, Israel, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma (NASDAQ/TASE: KTOV), an innovative biopharmaceutical...
Kitov to Present Data on NT219 in Combination with Keytruda® and Erbitux® at AACR International Cancer Immunotherapy Conference
26 sept. 2018 09h40 HE
|
Kitov Pharma Ltd.
Treatment with NT219 in combination with Keytruda® or Erbitux® converted non-responding tumors to responders TEL AVIV, Israel, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma (NASDAQ/TASE:...